The effect of nirmatrelvir plus ritonavir on the long-term risk of epilepsy and seizure following COVID-19: A retrospective cohort study including 91,528 patients
- PMID: 36649824
- PMCID: PMC9840225
- DOI: 10.1016/j.jinf.2023.01.014
The effect of nirmatrelvir plus ritonavir on the long-term risk of epilepsy and seizure following COVID-19: A retrospective cohort study including 91,528 patients
Figures
Comment on
-
Efficacy and safety of Paxlovid for COVID-19:a meta-analysis.J Infect. 2023 Jan;86(1):66-117. doi: 10.1016/j.jinf.2022.09.027. Epub 2022 Sep 30. J Infect. 2023. PMID: 36191676 Free PMC article. No abstract available.
References
-
- Fernández-de-Las-Peñas C., Martín-Guerrero J.D., Cancela-Cilleruelo I., Moro-López-Menchero P., Rodríguez-Jiménez J., Navarro-Pardo E., et al. Exploring the recovery curves for long-term post-COVID functional limitations on daily living activities: the LONG-COVID-EXP-CM multicenter study. J Infect. 2022;84(5):722–746. - PMC - PubMed
-
- Xie Y., Choi T., Al-Aly Z.. Nirmatrelvir and the risk of post-acute sequelae of COVID-19. medRxiv 2022:2022.11.03.22281783.